Dr. Allen Davidoff reports

XORTX REPORTS THAT INDEPENDENT PROXY ADVISORY FIRMS RECOMMEND XORTX SHAREHOLDERS VOTE "FOR" THE SHARE CONSOLIDATION

Independent proxy advisory firms, including Institutional Shareholder Services (ISS) have recommended shareholders vote for on the share consolidation at the coming shareholder meeting scheduled for March 24, 2026.

Independent third party proxy advisory recommendations

In relation to the share consolidation, ISS recommended voting for this resolution, stating, "... The stock consolidation should have no direct impact on shareholder value and could enhance the long-term growth prospects of the company by broadening its financing alternatives."

ISS is a leading independent proxy voting and corporate governance advisory firm whose shareholder voting recommendations and analysis are subscribed to, and are relied upon, by many pension funds, investment managers, mutual funds and other institutional shareholders.

Dr. Allen Davidoff, chief executive officer of XORTX, stated: "We are pleased to receive the news that an independent third party proxy advisory firm, ISS, has recommended shareholders vote for all of the proposed resolutions. This endorsement truly underscores the strength of our proposals and affirms their alignment with shareholder interests. We appreciate the support and confidence expressed by these respected advisory firms."

Shareholders encouraged to vote ahead of the proxy deadline

The board of directors of XORTX recommends that shareholders vote for all resolutions.

The proxy voting deadline is March 20, 2026. Shareholders are encouraged to vote well in advance of the proxy voting deadline to ensure your vote is submitted in a timely manner. Voting is easy. Shareholders may vote on-line, by telephone, or any other methods provided in the form or proxy or voting instruction that have been included as part of the mailing.

Shareholders of record as of the close of business on Feb. 20, 2026, are eligible to vote at the meeting.

Shareholder questions and voting assistance

Shareholders with questions or who require voting assistance may contact Laurel Hill Advisory Group, XORTX's proxy solicitation agent.

North America toll-free:  1-877-452-7184

Outside North America:  1-416-304-0211

Text message:  text INFO to 416-304-0211 or 1-877-452-7184

E-mail:  assistance@laurelhill.com

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) the company's lead program, XRx-026, for the treatment of gout; (2) the XRx-008 program for ADPKD (autosomal dominant polycystic kidney disease); and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, the company is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.